About Eternox - Innovative Business Model and Vision
Eternox, founded by Dr. Hankil Jung—an intensivist and physician-scientist at Seoul National University Bundang Hospital—is developing ‘ROSorber,’ a first-in-class solution that removes reactive oxygen species (ROS) to fundamentally treat septic shock.
With 100% survival demonstrated in refractory septic shock animal models, the team aims to cut sepsis mortality by more than half. Recognizing the strong potential to set a new standard of care in a market where existing treatments show limited effectiveness, we decided to invest.
